Skip to Content

EGFR Mutational Analysis

Indication

Mutations (point mutations, insertions, deletions) in exons 18-21 of the epidermal growth factor receptor (EGFR) gene are found in a subset of non-small cell lung cancer (NSCLC). Mutations are found in KRAS wildtype tumors and are more frequently seen in patients without a smoking history. The presence of EGFR mutations may confer an improved response to EGFR-targeted therapy.

Methodology

PCR-based DNA Sanger sequencing.  This assay also available on the Next Gen Sequencing panel for Solid Tumors (Codons 108, 289, 598, 709-719, 730, 733-735, 742, 745-759, 769-774, 790, 810, 858, 861).

Test Parameters

This assay will detect mutations in exons 18-21 of the EGFR gene. The sensitivity of detection is approximately one mutated cell per five total cells in the sample.

Turnaround Time

10 days

Sample Requirements

Formalin-fixed, paraffin embedded tissue blocks containing adequate amounts of tumor to be analyzed (see above sensitivity), with areas to be tested indicated. Comparison of normal and tumor, or several different areas of tumor can be done, for additional charge.

Please provide a copy of the corresponding pathology report.

CPT Codes

81235

Additional charges may apply for tissue extraction.

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.


© 2014 The University of Texas MD Anderson Cancer Center